57 results about "Pancreatic progenitor cell" patented technology

Human proIslet Peptides (HIP) and HIP analogs and derivatives thereof, derived from or homologous in sequence to the human REG3A protein, chromosome 2p12, are able to induce islet neogenesis from endogenous pancreatic progenitor cells. Human proIslet Peptides are used either alone or in combination with other pharmaceuticals in the treatment of type 1 and type 2 diabetes and other pathologies related to aberrant glucose, carbohydrate, and/or lipid metabolism, insulin resistance, overweight, obesity, polycystic ovarian syndrome, eating disorders and the metabolic syndrome.

The invention relates to the discovery that the proliferation and survival of pancreatic progenitor cells can be enhanced by contacting the cells with, (1) a caspase inhibitor sufficient to reduce apoptosis in the pancreatic endocrine cells; and, (2) a growth factor in an amount sufficient to increase the level of activated Akt in the pancreatic endocrine cells.

The present invention relates to a substantially pure population of viable pancreatic progenitor cells, and methods for isolating such cells. The present invention further concerns certain therapeutic uses for such progenitor cells, and their progeny.

A method of generating pancreatic progenitor cells is disclosed. The method comprises:

• • (a) differentiating stem cells under conditions such that at least a portion of the cells express glucose transporter 2 (GLUT2) so as to generate GLUT2-expressing cells; and
  • (b) enriching for the GLUT2-expressing cells so as to generate a population of GLUT2 enriched cells, wherein at least 80% of the population of GLUT2 enriched cells express GLUT2, thereby generating pancreatic progenitor cells.

Isolated populations of cells generated according to the method, pharmaceutical compositions comprising same and uses thereof are also disclosed.

The present invention relates to a method for preparing highly pure pancreatic progenitor cells by using pluripotent stem cells such as ES cells or iPS cells as a source, inducing their differentiation into pancreatic progenitor cells, and culturing and proliferating the pancreatic progenitor cells. Specifically, the present invention relates to a method for proliferation of pancreatic progenitor cells, comprising the step of culturing the pancreatic progenitor cells in a medium containing (i) an EGF signal transduction activator and/or an FGF signal transduction activator and (ii) a ROCK inhibitor.

Certain embodiments disclosed herein are directed to a method of producing endoderm cells, such as definitive endoderm cells by exposing stem cells such as embryonic stem cells or induced pluripotent stem (iPS) cells to an effective amount of at least one compound described herein to differentiate the stem cells into the endoderm cells such as definitive endoderm cells. Differentated endoderm cells produced by the methods disclosed herein can be differentiated into pancreatic epithelium, and other endoderm derivatives such as thymus, liver, stomach, intestine and lung. Another aspect of the present invention relates to a method of producing pancreatic progenitor cells, such as Pdx1-positive pancreatic progenitor cells by exposing endoderm cells, such as definitive endoderm cells to an effective amount of at least one compound described herein to differentiate the definitive endoderm cells into Pdx1-positive pancreatic progenitor cells. Kits and compositions comprising Pdx1-positive pancreatic progenitor produced using the methods are also described.

Disclosed herein are compositions and methods for the generation of insulin positive β cells, for example by exposing Pdx+ pancreatic progenitor cells to one or more compounds, and compositions and kits comprising isolated populations of insulin positive cells.

The invention relates to the technical field of stem cells, and especially relates to culture media and applications thereof, and differentiation methods of induced pluripotent stem cells into pancreatic islets. In the provided differentiation methods, a differentiation process from iPS stem cells to pancreatic progenitor cells needs 14 days (2 weeks); and the process mainly includes following four steps:directional endoderm - archenteric canal -foregut/hindgut - pancreatic progenitor cells. The differentiation process from the pancreatic progenitor cells to functional islets needs about 31 days (1 month); and the process is mainly divided into following three steps: endocrine progenitor cells - early islets - islets in late functional maturity. Each of the above steps needs specific induction culture media; and the culture media can be formed by adding corresponding inducing factors into basic media, and the corresponding culture media need to be daily replaced for culture. Feeder layer cells are not needed during the whole induction of the method; and the adopted culture media have no animal-derived components, so that the risks of alloimmunization can be reduced.

This invention relates to the in vitro differentiation of pluripotent cells into pancreatic progenitors by i) culturing pluripotent cells in a definitive endoderm (DE) medium comprising a TGFp ligand, fibroblast growth factor ( FGF), bone morphogenetic protein (BMP), a PI3K inhibitor and optionally a GSK3 β inhibitor to produce a population of definitive endoderm cells, ii) culturing the definitive endoderm cells in a first pancreatic medium comprising an activin antagonist; FGF; retinoic acid; and a BMP inhibitor to produce a population of dorsal foregut cells; iii) culturing the dorsal foregut cells in a second pancreatic medium comprising FGF, retinoic acid, a BMP inhibitor, and a hedgehog signalling inhibitor, and; iv) culturing the endoderm cells in a third pancreatic medium comprising FGF. The progenitor cells thus produced may be further differentiated into pancreatic endocrine cells. These methods may be useful, for example, in producing pancreatic cells for therapy or disease modelling.

The invention relates to the field of biomedicine, in particular to a method for inducing human mesenchymal stem cells to differentiate into insulin-secreting cells in vitro, which includes, according to the technical scheme, constructing recombinant eukaryotic expression plasmids of SRF (serum response factor) gene; preliminarily inducing human mesenchymal stem cells into nestin cells first; further inducing the nestin cells into pancreatic progenitor cells; transfecting an eukaryotic expression vector containing the SRF gene to the cells above; and finally inducing the cells into insulin-secreting cells, wherein the eukaryotic expression vector comprises pEGFP (plasmid enhanced green florescence protein), pcDNA or pCMV. By the method, new seed cell sources for cell therapy of diabetes mellitus are provided, new theoretical and experimental basis is provided for directed induction of mesenchymal stem cells differentiating into insulin-secreting cells and clinical application of the insulin-secreting cells, and new models for drug development and screening related to the insulin-secreting cells are provided.

The invention is directed to methods for generating pancreatic progenitor cells, insulin producing cells or endoderm cells using embryonic stem cells and induced pluripotent stem cells. The present invention also relates to an isolated population comprising pancreatic progenitor cells or a insulin-producing cells, compositions and their use in the treatment of diabetes

The present invention provides mammalian pancreatic progenitor cells (“small cells”) and methods for their isolation and propagation. The pancreatic small cells are derived from adult pancreatic tissue and are characterised by their small size. The small cells are quiescent or undergo a very slow cell cycle when maintained in cell culture. Small cells secrete synaptophysin and islet hormones and are predominantly found in small, growing islets as small clusters. The present invention further provides for the use of the pancreatic small cells in transplantation and the treatment of diabetes mellitus, and for the genetic engineering of the small cells in order to produce recombinant proteins in vivo.

The invention discloses a substantially pure population of human pancreatic progenitor cells and methods of isolating and culturing the pancreatic progenitor cells. By carefully manipulating the microenvironment of the pancreatic progenitor cells, multiple passages are attainable wherein the pancreatic progenitor cells do not senesce and furthermore, are capable of becoming functional exocrine or endocrine cells. In addition, several methods of use of human pancreatic progenitor cells are disclosed herein.

Provided is a method for inducing pancreatic hormone-producing cells from pancreatic progenitor cells efficiently. The method comprises a step of culturing the cells in a culture medium comprising sodium cromoglicate.

There is described herein a method for enriching/purifying a population of cells for pancreatic progenitor cells, the method comprising: a) providing the population cells, the population comprising pancreatic progenitor cells; and b) performing at least one of steps (i)-(v): (i) selecting for cells from the population that express at least one protein listed in cluster 2; (ii) selecting for cells from the population that express at least one protein listed in cluster 5; (iii) deselecting for cells from the population that express at least one protein listed in cluster 1; (iv) deselecting for cells from the population that express at least one protein listed in cluster 3; and (v) deselecting for cells from the population that express at least one protein listed in cluster 6.